	C 2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Total Revenue	1,093	1,049	1,112	1,853	2,012	1,966	1,969	2,082	2,152	2,239	2,611	2,425	2,193	2,281	2,520
Cost of Operating Revenue	426	341	433	941	911	927	867	887	954	967	1,122	1,032	904	920	996
Gross Profit	667	708	678	911	1,101	1,039	1,101	1,195	1,198	1,272	1,489	1,393	1,289	1,361	1,524
Gross Margin	61.0	67.5	61.0	49.2	54.7	52.9	56.0	57.4	55.7	56.8	57.0	57.5	58.8	59.7	60.5
Total Operating Expenses	908	874	880	1,599	1,633	1,679	1,532	1,582	1,677	1,636	1,889	1,720	1,616	1,600	1,673
Operating Profit	186	175	231	253	379	288	437	499	475	603	722	705	577	681	847
Operating Margin	17.0	16.7	20.8	13.7	18.8	14.6	22.2	24.0	22.1	26.9	27.7	29.1	26.3	29.9	33.6
Financing Income/(Expense) - Net	78	120	85	42	55	87	98	122	114	24	37	71	116	149	156
Profit before Taxes	278	1,388	340	238	470	517	548	660	642	669	773	824	746	1,016	976
Income Taxes	93	191	119	138	165	180	188	231	133	171	160	200	195	248	253
Profit after Tax	200	1,197	221	70	305	337	360	429	509	498	613	624	551	768	722
PAT Margin	18.3	114.1	19.9	3.8	15.2	17.1	18.3	20.6	23.7	22.2	23.5	25.7	25.1	33.6	28.7
EPS - Basic - ex Extraordinary Items	61.86	84.31	74.01	21.93	66.66	73.61	78.70	93.78	111.28	108.77	133.89	136.38	120.51	167.79	157.92
EPS - Diluted - ex Extraordinary Items	56.78	200.55	74.01	21.93	66.66	73.61	78.70	93.78	111.28	108.77	133.89	136.38	120.51	167.79	157.92
EBIT	186	175	231	253	379	288	437	499	475	603	722	705	577	681	847
EBITDA	205	191	238	383	435	349	502	569	577	711	836	809	639	742	905
EBITDA Margin	18.7	18.2	21.4	20.7	21.6	17.8	25.5	27.4	26.8	31.7	32.0	33.3	29.1	32.5	35.9

Balance Sheet

Abridged

Understanding Balance Sheet

Pfizer Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	R 2013 Mar 31	R 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	IR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	1,331	1,804	685	1,251	1,632	2,051	2,417	2,717	3,048	1,925	2,361	2,493	2,738	3,513	3,803
Long-Term Investments	48	46	44	43	37	35	34	32	31	30	45	13	14	14	15
Property Plant & Equipment - Net	31	26	23	88	102	87	83	71	215	195	220	185	151	179	156
Total Non-Current Assets	251	255	291	1,293	1,256	1,210	1,273	1,223	1,357	1,341	1,539	1,507	1,491	1,398	1,119
Total Assets	1,582	2,060	977	2,543	2,888	3,261	3,690	3,940	4,405	3,266	3,901	4,001	4,229	4,911	4,922
Total Current Liabilities	251	351	303	540	658	780	954	892	873	774	853	657	547	570	627
Long Term Debt	-	-	-	3	3	-	-	-	89	43	128	93	54	68	36
Total Non-Current Liabilities	26	14	15	82	66	62	52	37	137	99	183	136	87	124	92
Total Liabilities	277	365	318	622	725	842	1,007	929	1,010	873	1,036	793	633	694	719
Total Shareholders' Equity	1,305	1,694	658	1,922	2,163	2,419	2,683	3,011	3,395	2,393	2,864	3,207	3,596	4,217	4,203
Total Equity	1,305	1,694	658	1,922	2,163	2,419	2,683	3,011	3,395	2,393	2,864	3,207	3,596	4,217	4,203
Total Liabilities & Equity	1,582	2,060	977	2,543	2,888	3,261	3,690	3,940	4,405	3,266	3,901	4,001	4,229	4,911	4,922

Cash Flow

Abridged

Understanding Cash Flow Statement

Pfizer Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	R 2013 Mar 31	2014 Mar 31	R 2015 Mar 31	C 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	335	126	452	193	333	259	411	464	515	561	667	448	621	735	1,096
Working Capital - Increase/(Decrease)	-124	-6	9	-40	69	149	10	-245	-52	-92	43	-34	-246	57	40
Net CF from Operating Activities	212	120	462	153	402	408	422	218	463	469	710	413	375	791	1,136
Capital Expenditures - Net	6	1	4	20	-67	-169	69	-27	2	18	13	64	-34	-124	24
Net CF from Investing Activities	392	1,100	9	-128	-757	-329	-328	-86	1,390	-513	-619	-107	-75	-211	-739
Dividends Paid - Cash - Total	28	41	2,322	1	50	69	92	91	103	1,519	160	297	183	160	752
Debt - LT & ST - Issuance/(Retirement) - Total	-	-	-	-	-	-	-	-	-39	-49	-20	-35	-41	-37	-38
Net Cash Flow from Financing Activities	-28	-86	-2,720	-1	-62	-83	-110	-110	-163	-1,568	-180	-332	-224	-198	-790
Free Cash Flow to Equity	206	119	457	132	469	577	352	245	422	402	677	314	368	878	1,074
Free Operating CF net dividend	177	77	-1,869	131	308	314	227	123	321	-1,068	535	51	173	603	359
Free Operating CF	205	118	453	132	358	383	319	214	424	451	695	348	356	763	1,111

Business Segment Analysis

FY End:

Mar 26

Pfizer Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 25.23 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 2,519.65 Cr

Assets

Pharmaceuticals (100.0%)₹ 4,921.88 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 847.00 Cr

Regional Segment Analysis

FY End:

Mar 26

Pfizer Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (96.2%)₹ 2,423.31 CrOutside of India (3.8%)₹ 96.34 Cr

Historical Segment Analysis

Track how Pfizer Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Pharmaceuticals	15	65	19	28	25

Frequently Asked Questions

What is the revenue of Pfizer Ltd.?

The latest trailing twelve month revenue of Pfizer Ltd. is ₹ 2,519.65 Cr, reflecting a 1-year growth of 10.45% and a 3-year CAGR of 1.29%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Pfizer Ltd.?

The latest trailing twelve month net profit (PAT) of Pfizer Ltd. is ₹ 722.43 Cr, with a 3-year earnings CAGR of 5.01%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Pfizer Ltd.?

The trailing twelve month EBITDA of Pfizer Ltd. is approximately ₹ 846.36 Cr (based on an operating margin of 33.59%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Pfizer Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Pfizer Ltd. is 157.92. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Pfizer Ltd.?

The debt-to-equity ratio of Pfizer Ltd. stands at 0.02. The interest coverage ratio is 89.28x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Pfizer Ltd.?

The estimated book value per share of Pfizer Ltd. is 918.71 (derived from a P/B ratio of 4.93 and market price of ₹ 4,532.10), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Pfizer Ltd.?

The trailing twelve month operating cash flow of Pfizer Ltd. is ₹ 1,136.06 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Pfizer Ltd. report consolidated or standalone financials?

Pfizer Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.